Sinopharm Group (Sinopharm) reported modest top-line softness and lower profitability for the six months ended 30 June 2026, as core distribution units faced persistent pricing pressure while retail pharmacies maintained double-digit momentum.
Financial highlights • Revenue fell 1.13% year on year (YoY) to RMB 282.80 billion, reflecting weaker pharmaceutical and medical-device distribution sales. • Gross profit declined 6.27% to RMB 19.07 billion; gross margin contracted 37 basis points to 6.74%. • Operating profit slipped 4.03% to RMB 7.15 billion; operating margin eased to 2.53% (-7 bps). • Net profit attributable to shareholders dropped 1.79% to RMB 3.40 billion; basic EPS decreased to RMB 1.09 (-1.80%). • Net finance costs narrowed 18.77% to RMB 808.72 million on lower interest rates. • No interim dividend was declared.
Segment performance • Pharmaceutical distribution: Revenue of RMB 215.50 billion (-1.39% YoY), accounting for 72.98% of group sales. Lower volumes from volume-based procurement and pricing controls outweighed rapid growth in national negotiated and innovative drugs. Segment operating margin slipped 16 bps to 2.42%.
• Medical device distribution: Revenue held broadly flat at RMB 56.85 billion (-0.35% YoY), contributing 19.25% of total. Centralised procurement for high-value consumables and large equipment exerted pricing pressure; operating margin narrowed 15 bps to 1.77%.
• Retail pharmacy: Revenue rose 8.58% to RMB 18.64 billion, lifting its contribution to 6.31%. Specialty pharmacies capitalised on prescription outflow and innovative-drug demand, driving segment operating margin up 32 bps to 3.00%. Guoda Drugstore store count fell by 246 to 7,975, while specialty pharmacies decreased by 21 to 1,440.
• Other businesses (lab supplies, reagents, manufacturing): Revenue increased 5.20% to RMB 4.29 billion.
Cost discipline and cash flow Selling and distribution expenses fell 6.67% to RMB 7.32 billion; administrative expenses dropped 5.37% to RMB 3.47 billion, trimming the overall expense ratio to 4.11% (-27 bps YoY). Net operating cash outflow improved to RMB 23.76 billion (1H25: outflow RMB 34.11 billion). Cash and cash equivalents stood at RMB 31.04 billion, down from RMB 48.80 billion at end-2025, while the gearing ratio inched up to 66.29% (end-2025: 65.63%).
Capital expenditure totalled RMB 1.58 billion (-12.60% YoY), focused on warehousing, logistics upgrades and pharmacy network optimisation.
Management outlook Sinopharm plans to deepen procurement and logistics integration, accelerate digital transformation and expand high-value services—such as CSO marketing, intelligent medical-device supply-chain solutions and third-party logistics—while prioritising risk control and cash-flow discipline. Retail operations will pursue dual-brand development, with Guoda Drugstore enhancing health-service offerings and specialty pharmacies targeting innovative and chronic-disease drugs.
No material post-reporting-period events, acquisitions or disposals were disclosed.
Comments